<DOC>
	<DOCNO>NCT01137695</DOCNO>
	<brief_summary>The hypothesis study obese patient type 2 diabetes mellitus respond FDA approve dose 120 mcg pramlintide ( Symlin® ) 3 time daily expect glucose control require high FDA approve dosage . The primary objective study determine whether high dos pramlintide ( Symlin® ) patient type 2 diabetes mellitus control glucose good FDA approve dose 120 mcg three time daily . The secondary objective include prove whether high dose pramlintide ( Symlin® ) efficacious cause weight loss reduction waist circumference standard dose pramlintide ( Symlin® ) , determine whether blood level certain hormone correlate need high dose therapy , determine whether rate common adverse effect exceed maximum FDA approve pramlintide ( Symlin® ) dose 120 mcg three time daily .</brief_summary>
	<brief_title>Efficacy Study High Dose Symlin Treat Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pramlintide</mesh_term>
	<mesh_term>Islet Amyloid Polypeptide</mesh_term>
	<criteria>1 . Age 1880 year . 2 . Type 2 diabetes mellitus . 3 . Obese ( BMI &gt; 30 kg/m2 ) , waist circ . &gt; 35 '' woman , &gt; 40 '' men . 4 . Basal insulin plus least 2 injection mealtime insulin daily premixed insulin . 5 . On stable insulin dose least 3 mo ( baseline + 20 % , minimum ) . 6 . If pramlintide treat , stable full dose least 3 month . 7 . A1c &gt; 7.0 % &lt; 9.0 % . 8 . Women childbearing age use reliable form birth control . 9 . Women childbearing age post tubal ligation surgical menopause . 10 . Able consent . 11 . Willing perform selfmonitoring glucose . 12 . Willing attend study visit . 13 . Written inform consent participate study . 14 . Agreement maintain prior diet exercise throughout full course study . 1 . Age &lt; 18 &gt; 80 year . 2 . Confirmed gastroparesis take medication affect gastric motility . 3 . A1c &lt; 7.0 % &gt; 9.0 % . 4 . Recurrent severe hypoglycemia hypoglycemic unawareness . 5 . CHF . 6 . Creatinine clearance &lt; 30 ml/min . 7 . History MI &lt; 6 mo prior enrollment . 8 . History ventricular arrhythmia . 9 . History cancer chemotherapy &lt; 6 mo prior enrollment . 10 . Laboratory abnormality follow : 1 . Liver enzymes &gt; 3X ULN . 2 . Hematocrit le 30 . 3 . Serum creatinine &gt; 2.5 mg/dl . 4 . Fasting triglyceride &gt; 500 mg/dl . 11 . Cirrhosis . 12 . Pregnancy nursing . 13 . Inability provide consent . 14 . Unwilling attend study visit . 15 . Unwilling perform selfmonitoring glucose . 16 . Chronic oral parenteral glucocorticoid therapy ( one week treatment ) within 3 month prior screen . 17 . Investigational drug treatment within 3 month prior screen . 18 . Donation blood , significant blood loss transfusion within 3 month screen . 19 . History acromegaly Cushing 's syndrome . 20 . Use prohibit concomitant medication . 21 . Type 1 diabetes mellitus . 22 . Acute metabolic complication ( hyperosmolar state ) &lt; 6 month prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>pramlintide</keyword>
	<keyword>glucose</keyword>
	<keyword>type 2 diabetes mellitus</keyword>
	<keyword>amylin</keyword>
</DOC>